Additional file 1 of Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment

Additional file 1: SI Materials 1. Antibodies used in DigiWest protein profiling analysis. Figure S1. Multicolor flow cytometry analysis of isolated and expanded TILs from BC specimen. Figure S2. Correlation of nuclear grade in PDM and PTT. Figure S3. Proteomic comparison of NST and ILC-derived BC PDM. Figure S4. Identification of resistance and sensitivity marker panels in treatment responder and non-responder microtumors and regression analysis of differently expressed proteins. Table S1. Clinical patient data of the patient cohort. Table S2. Descriptive statistics of “area” and “fluorescent intensity live/dead” measurements in PDM. Table S3. Raw data of DigiWest® protein signals in PDM and PTT samples and total measured protein amounts. Table S4. DigiWest®-based AFI protein signals in matched PDM-PTT pairs DigiWest®-based AFI protein signals in matched PDM-PTT pairs. Table S5. DigiWest®-based AFI protein signals of matched PDM-PTT pairs sorted by pathway affiliation. Table S6. Pearson correlation of protein abundances in PDM and corresponding PTT (PDM/PTT pairs). Table S7. DigIWest®-based AFI protein signals of n = 42 PDM samples. Table S8. Descriptive statistics of averaged, median-centered and log2 transformed protein signals for cell cycle, MAPK/RTK and PI3K/AKT pathway in n = 42 PDM samples. Table S9. Celltox™ Green assay RFU (relative fluorescent unit) values of BC microtumors treated with TAM, DTX, PTX and PAB. Table S10. Descriptive statistics of simple logistic regression analysis of differentially expressed proteins in treatment responder and non-responder groups.